Stock·NYSE·Financial Services
The Allstate Corporation (ALL)
- Market cap
- $62.68B
- P/E
- 4.73
- Dividend yield
- 1.71%
- Street target
- $270.50median of 25 analysts
- 52-week range
- $188.08 $277.22
The short version
Where ALL stands today, in four lines, and what CleaRank Financial AI makes of it.
ALL at a glance
The Allstate Corporation (ALL): Strong Buy, 80/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($246.92 and $225.96).
- Earnings ALL beat estimates in 8 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $138.5M and made no open-market purchases over the last 18 months.
- Valuation P/E of 4.7 against 16.5 for the Financial Services sector: a discount to peers (-71%).
Figures as of October 16, 2026.
CleaRank Financial AI
ALL, The Allstate Corporation, earns a CleaRank rating of Strong Buy with a model score of 80/100.
Its trend contributes the most to that score. The price sits 9.70% above the 200-day average and 0.39% above the 50-day average, while the 50-day average is 9.28% above the 200-day, which stands at $225.96. The 50-day average is $246.92. Over the past year, the price climbed 27.20%.
Only on CleaRank
Figures we compute ourselves from ALL's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $247.88 is 0.4% above the 50-day simple moving average of $246.92.Price above its 200-day average ›
The price is 9.7% above the 200-day simple moving average of $225.96.50-day average above the 200-day ›
The 50-day average ($246.92) is 9.3% above the 200-day average ($225.96), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 67% of its 52-week range, between $188.08 and $277.22.
ALL share price
Pick a period: each tab shows how far ALL has moved over it, to the last close.
Today's trading
Where ALL sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 4.73 is 71.4% below the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 0.85 is 77.6% below the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $13.2B on revenue of $70.1B, a net margin of 18.8%.Beat estimates in most recent reports ›
ALL beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.71%, or $4.24 a share a year.
Key statistics
The headline figures for ALL.
As of October 16, 2026, ALL trades at $247.88, with a market value of $62.68B, a P/E ratio of 4.73 and a dividend yield of 1.71%.
What the numbers say
CleaRank Financial AI's reading of ALL's valuation, growth and risks.
ALL trades at 4.73 times trailing earnings, which leaves the P/E 71.4% below the Financial Services median of 16.5. The Peer Benchmarking card classes that as a discount to peers. Measured against sales, the P/S of 0.85 is 77.6% below the sector median of 3.8. Trailing earnings stand at $49.98 a share.
In the latest year revenue grew 11.80%, 0.1 percentage points faster than the sector median of 11.7%. Profitability shows a net margin of 18.97% and an operating margin of 22.83%, with a return on equity of 46.11%, above the sector median of 13.8%. Debt-to-equity of 0.22 and a trailing dividend yield of 1.71% ($4.24 a share a year) round out the fundamentals.
ALL's August 5, 2026 report topped expectations by 48.11%, with $8.99 a share reported against an estimate of $6.07. Investors responded positively, and the stock climbed 3.98% in the next session.
Across its last 8 reports, ALL beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 3 of them. Analysts' average EPS estimate for this fiscal year is $35.38, which would be growth of 1.6%, and $28.05 for next year (a decline of 20.7%).
Daily returns on ALL have a 30-day standard deviation of 1.73%. Insider sales came to $138.5M over the last 18 months, and there were no open-market purchases. Insider selling is often planned in advance or made to cover tax on vesting shares, so it is a weaker signal than open-market buying.
ALL against the Financial Services sector
How ALL compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: ALL trades at a notable discount to sector peers (-71%), which may indicate undervaluation or specific company headwinds.
Return vs XLF: Since May 6, 2025, ALL has gained 22.7% against a gain of 12.5% for XLF.
Performance against XLF
ALL and the Financial Services sector fund over the same days.
Revenue and earnings
How much ALL sells, and how much of it becomes profit.
Revenue growth: Revenue grew 5.6% in FY2025 to $67.1B, from $63.5B a year earlier.
Profit margin: The net margin was 15.3% in FY2025, up from 7.2% the year before.
Profitable: ALL earned $10.3B in FY2025.
Earnings reality check
Did ALL beat what analysts expected, and how did the stock react?
Earnings record: ALL beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $6.07 | $8.99 | +48.11% | +3.98% | -3.31% |
| Apr 29, 2026after close | $7.24 | $10.65 | +47.10% | +2.32% | +2.63% |
| Feb 4, 2026after close | $10.21 | $14.37 | +40.74% | +3.90% | -1.15% |
| Nov 5, 2025after close | $7.57 | $13.95 | +84.28% | +1.67% | +7.42% |
| Jul 30, 2025after close | $3.87 | $7.76 | +100.52% | +5.71% | +8.70% |
| Apr 30, 2025after close | $2.53 | $3.53 | +39.53% | -0.58% | +2.86% |
| Feb 5, 2025after close | $6.15 | $7.07 | +14.96% | -0.59% | -1.91% |
| Oct 30, 2024after close | $1.93 | $4.39 | +127.46% | -1.54% | -0.34% |
As of October 16, 2026, ALL has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 5, 2026, came in 48.11% above the estimate and the stock moved +3.98% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 63.2, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 63.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ALL
The score, the reasoning behind it, and what could move the price next.
ALL is in an uptrend: the price of $247.88 sits 0.39% above its 50-day average of $246.92 and 9.70% above its 200-day average of $225.96. Both averages lie beneath the price, and the 50-day average is 9.28% above the 200-day. Across the 52-week range, which runs from $188.08 up to $277.22, today's price stands at 67% of the way up.
A recent pullback sits inside a stronger longer record: the price fell 2.73% over the past month, fell 0.81% over the past three months and rose 27.20% over the past year. On momentum, the 14-day RSI reads 63.2, in the bullish zone, below the overbought line, although the MACD line is negative, which pulls the other way. The price rose 3.46% in the last session on volume 81.4% above its average.
Earnings beat ›
The August 5, 2026 report beat the EPS estimate by 48.11%, and the share price rose 3.98% in the first session after it.
Source: Earnings report, August 5, 2026Analyst upgrade ›
Wells Fargo upgraded it to Equal-Weight from Underweight on October 12, 2026.
Source: Analyst action, Wells Fargo, October 12, 2026
No risks flagged.
- Keep an eye on the two closest levels: the 52-week high at $277.22 overhead and the 50-day SMA at $246.92 underneath.
- A 14-day RSI of 63.2 lands in the bullish zone, while the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- The share price rose 3.98% in the first session after the August 5, 2026 report, and ALL has beaten estimates in 8 of its last 8 reports.
ALL sits above its 50-day and 200-day moving averages ($246.92 and $225.96), at $246.92 and $225.96, and that alignment is why the trend reads as up. A slip below the 50-day would be the first sign of weakness. The closest level beneath the price is the 50-day SMA, at $246.92.
The next level overhead is the 52-week high at $277.22. An RSI in the bullish band supports the current direction without signalling that the stock is stretched.
Technical indicators
Momentum and trend for ALL, from its daily closes.
As of October 16, 2026, with ALL at $247.88, its 14-day RSI is 63.2 (showing bullish momentum without being overbought), its 50-day simple moving average is $246.92 and its 200-day is $225.96.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ALL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, ALL's 1-year correlation of daily returns is +0.17 with S&P 500 (SPY), -0.01 with Nasdaq 100 (QQQ), -0.24 with Bitcoin (BTC) and -0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
11 of 25 analysts rate it a buy or strong buy, 9 a hold and 5 a sell.Median target above the price ›
The median 12-month target of $270.50 is 9.1% above the price.More buy ratings than three months ago ›
11 of 25 rate it a buy now, against 10 of 25 three months ago.
ALL Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | Wells Fargo | Upgrade | Equal-Weight |
| Oct 12, 2026 | Keefe, Bruyette & Woods | Maintains | Underperform |
| Oct 7, 2026 | Mizuho | Maintains | Outperform |
| Oct 7, 2026 | Barclays | Maintains | Underweight |
| Oct 6, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Oct 2, 2026 | Citigroup | Maintains | Sell |
As of October 16, 2026, 25 Wall Street analysts cover ALL: 11 rate it a buy or strong buy, 9 a hold and 5 a sell or strong sell. Their 12-month price targets range from $191.00 to $336.00, with a median of $270.50, 9.1% above the price of $247.88.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ALL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ALL's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ALL tends to move, against the market and on its own.
The long record
ALL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.73% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.8%, from February 2020 to March 2020, regained by April 2021.Most 1-year holds ended higher ›
78% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $42,992, against $42,525 in the S&P 500 (SPY).
ALL Drawdowns & Recovery
As of October 16, 2026, ALL's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.8% (February 2020 to March 2020); it regained that peak by April 2021, 13 months after the low, and 78% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ALL in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ALL beat the S&P 500 over this period: $42,992 against $42,525.
A $10,000 investment in ALL in October 2016 would be worth about $42,992 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ALL, and which have not.
Strongest month, November: an average of +5.17%, up in 8 of 10 years.
Weakest month, October: an average of -1.31%, up in 4 of 9 years.
This month, October: has averaged -1.31%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ALL's strongest calendar month has been November (average +5.17%, up in 8 of 10 years) and its weakest October (average -1.31%, up in 4 of 9 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ALL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ALL today could grow to about $23,157 by 2036 in the base case, with a 90th-percentile outcome near $65,318 and a 10th-percentile outcome around $8,210. The simulation models price only; at today's 1.71% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ALL Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $347 for ALL by 2030 in the base case, from $248 today (1.4x over 4 years). The 10th-percentile path ends near $180. These are outcomes of a Monte Carlo simulation run on ALL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $194 | $270 | $374 | |
| 2028 | $184 | $293 | $466 | |
| 2029 | $181 | $319 | $563 | |
| 2030 | $180 | $347 | $668 | |
| 2031 | $181 | $377 | $785 |
Method: a lognormal simulation of ALL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ALL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought ALL shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, ALL insiders reported 29 open-market sales worth $138.5M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | John E Dugenske
Divisional Officer
|
Grant | 1.6K | - |
| Oct 2, 2026 | Zulfikar Jeevanjee
Chief Technology Officer
|
Grant | 2.4K | - |
| Oct 2, 2026 | Jesse E Merten
Divisional Officer
|
Grant | 18 | - |
| Oct 2, 2026 | Mario Rizzo
Chief Operating Officer
|
Grant | 19 | - |
| Oct 1, 2026 | Margaret M Keane
Director
|
Grant | 150 | $33.7K |
| Oct 1, 2026 | Jacques P Perold
Director
|
Grant | 189 | $42.4K |
| Oct 1, 2026 | Perry M Traquina
Director
|
Grant | 183 | $41.1K |
| Sep 4, 2026 | Zulfikar Jeevanjee
Officer of Subsidiary Company
|
Grant | 483 | - |
| Sep 3, 2026 | Margaret M Keane
Director
|
Grant | 944 | - |
| Aug 11, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Sell | 56.2K | $14.9M |
| Aug 11, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Option | 56.2K | $5.2M |
| Aug 7, 2026 | John E Dugenske
Divisional Officer
|
Sell | 33.0K | $8.9M |
| Jul 1, 2026 | Margaret M Keane
Director
|
Grant | 138 | $33.6K |
| Jul 1, 2026 | Jacques P Perold
Director
|
Grant | 174 | $42.3K |
| Jul 1, 2026 | Perry M Traquina
Director
|
Grant | 169 | $41.1K |
| Jun 30, 2026 | Perry M Traquina
Director
|
Grant | 2.0K | - |
| Jun 5, 2026 | Eric K Ferren
Officer
|
Grant | 245 | - |
| Jun 4, 2026 | Andrea M Carter
Officer of Subsidiary Company
|
Grant | 4.0K | - |
| Jun 1, 2026 | Andrea Redmond
Director
|
Sell | 2.2K | $451.5K |
| Jun 1, 2026 | Richard T Hume
Director
|
Grant | 1.6K | - |
| Jun 1, 2026 | Margaret M Keane
Director
|
Grant | 1.6K | - |
| Jun 1, 2026 | Jacques P Perold
Director
|
Grant | 1.6K | - |
| Jun 1, 2026 | Andrea Redmond
Director
|
Grant | 2.2K | - |
| Jun 1, 2026 | Monica J Turner
Director
|
Grant | 1.6K | - |
| May 22, 2026 | Mark Q Prindiville
Former
|
Sell | 1.6K | $335.2K |
| May 22, 2026 | Mark Q Prindiville
Former
|
Option | 1.6K | $107.4K |
| May 1, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Sell | 18.6K | $4.1M |
| May 1, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Option | 18.6K | $1.7M |
| Apr 1, 2026 | Margaret M Keane
Director
|
Grant | 165 | $33.7K |
| Apr 1, 2026 | Jacques P Perold
Director
|
Grant | 208 | $42.5K |
| Apr 1, 2026 | Perry M Traquina
Director
|
Grant | 202 | $41.2K |
| Mar 16, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.5M |
| Mar 2, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.6M |
| Feb 25, 2026 | Jesse E Merten
Divisional Officer
|
Sell | 34.0K | $7.1M |
| Feb 25, 2026 | Jesse E Merten
Divisional Officer
|
Option | 35.2K | $4.5M |
| Feb 24, 2026 | Elizabeth Brady
Divisional Officer
|
Grant | 476 | - |
| Feb 24, 2026 | Christine Marie Debiase
General Counsel
|
Grant | 728 | - |
| Feb 24, 2026 | John E Dugenske
Officer
|
Grant | 1.0K | - |
| Feb 24, 2026 | Eric K Ferren
Officer
|
Grant | 221 | - |
| Feb 24, 2026 | Suren K Gupta
Divisional Officer
|
Grant | 680 | - |
| Feb 24, 2026 | Zulfikar Jeevanjee
Chief Technology Officer
|
Grant | 565 | - |
| Feb 24, 2026 | Mark Q Prindiville
Executive Vice President
|
Grant | 402 | - |
| Feb 24, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Grant | 1.3K | - |
| Feb 20, 2026 | Elizabeth Brady
Divisional Officer
|
Grant | 662 | - |
| Feb 20, 2026 | Christine Marie Debiase
General Counsel
|
Grant | 905 | - |
| Feb 20, 2026 | John E Dugenske
Chief Financial Officer
|
Grant | 1.6K | - |
| Feb 20, 2026 | Suren K Gupta
Divisional Officer
|
Grant | 942 | - |
| Feb 20, 2026 | Zulfikar Jeevanjee
Officer of Subsidiary Company
|
Grant | 754 | - |
| Feb 20, 2026 | Jesse E Merten
Divisional Officer
|
Grant | 1.5K | - |
| Feb 20, 2026 | Mark Q Prindiville
Executive Vice President
|
Grant | 571 | - |
| Feb 20, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Grant | 1.8K | - |
| Feb 17, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.5M |
| Feb 13, 2026 | Elizabeth Brady
Divisional Officer
|
Grant | 8.9K | - |
| Feb 13, 2026 | Christine Marie Debiase
General Counsel
|
Grant | 11.6K | - |
| Feb 13, 2026 | John E Dugenske
Chief Financial Officer
|
Grant | 19.6K | - |
| Feb 13, 2026 | Suren K Gupta
Divisional Officer
|
Grant | 14.6K | - |
| Feb 13, 2026 | Zulfikar Jeevanjee
Officer of Subsidiary Company
|
Grant | 7.6K | - |
| Feb 13, 2026 | Jesse E Merten
Divisional Officer
|
Grant | 15.8K | - |
| Feb 13, 2026 | Mark Q Prindiville
Officer of Subsidiary Company
|
Grant | 7.2K | - |
| Feb 13, 2026 | Mario Rizzo
Officer of Subsidiary Company
|
Grant | 19.6K | - |
| Feb 13, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Grant | 85.9K | - |
| Feb 3, 2026 | Christine Marie Debiase
General Counsel
|
Grant | 2.5K | - |
| Feb 2, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.4M |
| Jan 30, 2026 | Monica J Turner
Director
|
Grant | 456 | - |
| Jan 12, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.5M |
| Jan 7, 2026 | Suren K Gupta
Divisional Officer
|
Sell | 19.6K | $4.1M |
| Jan 7, 2026 | Suren K Gupta
Divisional Officer
|
Option | 19.6K | $1.2M |
| Jan 2, 2026 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.4M |
| Dec 31, 2025 | Margaret M Keane
Director
|
Grant | 162 | $33.7K |
| Dec 31, 2025 | Jacques P Perold
Director
|
Grant | 204 | $42.5K |
| Dec 31, 2025 | Perry M Traquina
Director
|
Grant | 198 | $41.2K |
| Dec 19, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Grant | 50.1K | - |
| Dec 15, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.5M |
| Dec 1, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.6M |
| Nov 28, 2025 | Suren K Gupta
Divisional Officer
|
Sell | 4.5K | $975.8K |
| Nov 28, 2025 | Suren K Gupta
Divisional Officer
|
Option | 4.5K | $282.7K |
| Nov 24, 2025 | Suren K Gupta
Divisional Officer
|
Sell | 600 | $129.0K |
| Nov 24, 2025 | Suren K Gupta
Divisional Officer
|
Option | 600 | $37.4K |
| Nov 21, 2025 | Suren K Gupta
Divisional Officer
|
Sell | 21.9K | $4.7M |
| Nov 21, 2025 | Suren K Gupta
Divisional Officer
|
Option | 21.9K | $1.4M |
| Nov 17, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.6M |
| Nov 17, 2025 | Suren K Gupta
Divisional Officer
|
Sell | 400 | $86.1K |
| Nov 17, 2025 | Suren K Gupta
Divisional Officer
|
Grant | 385 | - |
| Nov 17, 2025 | Suren K Gupta
Divisional Officer
|
Option | 400 | $24.9K |
| Nov 14, 2025 | Suren K Gupta
Divisional Officer
|
Sell | 1.4K | $301.0K |
| Nov 14, 2025 | Suren K Gupta
Divisional Officer
|
Option | 1.4K | $87.2K |
| Nov 3, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.2M |
| Nov 3, 2025 | Zulfikar Jeevanjee
Officer of Subsidiary Company
|
Grant | 5.1K | - |
| Oct 20, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.3M |
| Oct 6, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 16.8K | $3.5M |
| Oct 3, 2025 | Jesse E Merten
Divisional Officer
|
Grant | 538 | - |
| Oct 3, 2025 | Mario Rizzo
Officer of Subsidiary Company
|
Grant | 199 | - |
| Oct 1, 2025 | Margaret M Keane
Director
|
Grant | 160 | $33.7K |
| Oct 1, 2025 | Perry M Traquina
Director
|
Grant | 195 | $41.1K |
| Sep 5, 2025 | Suren K Gupta
Divisional Officer
|
Grant | 13.9K | - |
| Aug 22, 2025 | Mark Q Prindiville
Officer of Subsidiary Company
|
Sell | 7.4K | $1.5M |
| Aug 22, 2025 | Mark Q Prindiville
Officer of Subsidiary Company
|
Option | 7.4K | $460.1K |
| Jul 1, 2025 | Margaret M Keane
Director
|
Grant | 168 | $33.6K |
| Jul 1, 2025 | Perry M Traquina
Director
|
Grant | 206 | $41.2K |
| Jun 5, 2025 | Eric K Ferren
Officer
|
Grant | 245 | - |
| Jun 2, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 181.5K | $38.0M |
| Jun 2, 2025 | Judith A. Sprieser
Director
|
Sell | 1.3K | $272.1K |
| May 30, 2025 | Richard T Hume
Director
|
Grant | 1.3K | - |
| May 30, 2025 | Margaret M Keane
Director
|
Grant | 1.3K | - |
| May 30, 2025 | Siddharth N Mehta
Director
|
Grant | 1.3K | - |
| May 30, 2025 | Gregg M Sherrill
Director
|
Grant | 1.3K | - |
| May 30, 2025 | Judith A. Sprieser
Director
|
Grant | 1.3K | - |
| May 29, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 24.7K | $5.1M |
| May 29, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Option | 295.3K | $18.4M |
| May 6, 2025 | Mario Rizzo
Divisional Officer
|
Grant | 1.8K | - |
| May 5, 2025 | Mario Rizzo
Divisional Officer
|
Option | 6.0K | $558.7K |
| Apr 21, 2025 | Thomas Joseph Wilson II
Chief Executive Officer
|
Sell | 31.5K | $6.0M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.